Abstract
Abstract
Background:‎
Diabetes mellitus (DM) is the highest prevalent endocrine illness that exhibits hyperglycemia, ‎hyperlipidemia and protein metabolism disorders also elevated risk of several complications, including ‎vascular disorders. A variety of polypeptide agents can be found in bee venom. The two main ingredients ‎of bee venom are phospholipase A2 and mellitin. These constituents enhance the release of insulin from ‎the Beta islands of pancreas. The purpose of the current work was to demonstrate the hypoglycemic and ‎hypolipidemic effects of bee venom on male diabetic rats that induced by alloxan. ‎
Methods:‎
‎ The experimental investigation was carried out on 40 male rats (weight from180 to 220 g) which were ‎assigned to four groups (10/each): (the first) a negative control group (not receiving therapy), (the ‎second) a positive control group (diabetic group) injected with alloxan only (160 mg/kg), (the third) ‎diabetic group administered with Vildagliptin (6mg/kg) and the forth diabetic group treated with Bee ‎venom (0.5mg/kg). After two months of the investigation, blood samples were assembled. ‎
Results:‎
Bee Venom (0.5mg/kg) lowered significantly (p≤0.05) the level of serum glucose, which was followed ‎by a substantial rise in the level of HDL and insulin when contrasted to the rats with diabetes. Total lipid, ‎cholesterol, triacylglycerol and LDL levels were considerably reduced in the diabetic group that received ‎BV.‎
Conclusion:‎
There is a growing interest in the bee venom's use as a natural product rather than chemical drugs for ‎treatment of diabetes mellitus because of the manner it affects rats biochemically, particularly its ‎prospective anti-diabetic and anti-hyperlipidemia qualities.‎

Key words: Bee venom; Alloxan; Vildagliptin; Diabetes type 2; oxidative stress, biochemical indices (insulin; lipid ‎profile).‎